Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.38 |
| ▸ | LPL | P06858 | 4/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
| ▸ | F11 | P03951 | 3/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14654744 | 0.87 | FFAR1 (0.52) | FFAR1LIPGLPLP4HBF11 | |
| SCHEMBL29108989 | 0.86 | FFAR1 (0.51) | FFAR1LIPGLPLP4HBF11 | |
| SCHEMBL23360827 | 0.84 | FFAR1 (0.39) | FFAR1 | |
| SCHEMBL29071418 | 0.83 | FFAR1 (0.49) | FFAR1LIPGLPLP4HBF11 | |
| SCHEMBL3095572 | 0.83 | LIPG (0.53) | FFAR1LIPGLPLP4HBF11 | |
| SCHEMBL1650157 | 0.81 | FFAR1 (0.50) | FFAR1LIPGLPLF11DGAT1 | |
| SCHEMBL28625603 | 0.80 | FFAR1 (0.43) | FFAR1 | |
| SCHEMBL860835 | 0.80 | FFAR1 (0.46) | FFAR1P4HBDGAT1IRAK4CA1 | |
| SCHEMBL28695626 | 0.80 | FFAR1 (0.35) | FFAR1 | |
| SCHEMBL15742131 | 0.79 | FFAR1 (0.51) | FFAR1LIPGLPLF11F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| EP-3644991-B1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3564233-B1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2023-05-03 | — | — | EP | disclosed |
| EP-3644992-B1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
| EP-4101849-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | Novartis AG (CH) | 2022-12-14 | — | — | EP | disclosed |
| US-20220387428-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| US-20220242850-A1 | PHTHALAZIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-04 | — | — | US | disclosed |
| CN-114728926-A | ROCK inhibitor and preparation method and application thereof | 武汉朗来科技发展有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-11339156-B2 | 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-2194045-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-06-09 | — | — | EP | disclosed |
| WO-2010011538-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY | 2010-01-28 | — | — | US | disclosed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| EP-2139332-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2008121257-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008094473-A1 | SUBSTITUTED PYRANO[2,3-B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| EP-1879885-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117306-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339156-B2 | 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor | CHRM4, CHRM3, CHRM5 | FFAR1 498/4885LIPG 4797/4885LPL 4210/4885 |
| US-20220242850-A1 | PHTHALAZIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS | GRK2, GRK4, GRK3 | FFAR1 340/4885LIPG 817/4885LPL 607/4885 |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | AR, NR5A1, NR3C2 | FFAR1 560/4885LIPG 4825/4885LPL 4718/4885 |
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROCK1, CYP11B1, CYP4A11 | FFAR1 269/4885LIPG 3315/4885LPL 4483/4885 |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | MET, MYCBP, MYC | FFAR1 2615/4885LIPG 3859/4885LPL 4634/4885 |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | VHL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DLD | FFAR1 4399/4885LIPG 1387/4885LPL 2023/4885 |
| US-20220387428-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, SF3B5 | FFAR1 3657/4885LIPG 4554/4885LPL 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.